Fractional CFO

Aphios Corporation is a clinical-stage biotechnology company advancing differentiated nanotechnology platforms and next-generation therapeutics across oncology, neurodegenerative disease, infectious disease, and substance-use disorder. As the company enters its next phase of growth and capital-markets readiness, Aphios is seeking an experienced Part-Time / Fractional Chief Financial Officer (CFO) with direct biotech IPO and public-company preparation experience to work closely with the CEO and Board. This role is designed for a senior biotech finance executive who has successfully guided companies through IPO preparation, public-company readiness, and alternative public-market pathways, and who is interested in a high-impact, flexible leadership engagement rather than a full-time operating role. Key Responsibilities: - Lead financial strategy, capital planning, and cash-flow management for a growth-stage biotech. - Prepare the company for IPO and public-company readiness, including internal controls, reporting infrastructure, and governance. - Oversee GAAP-compliant financial reporting, audit readiness, and risk management. - Develop and maintain long-range financial models aligned with clinical, regulatory, and commercialization milestones. - Support investor relations, Board communications, and external stakeholder engagement. - Structure and evaluate PIPE financings, crossover fund participation, and late-stage private capital strategies. - Advise on NASDAQ and NYSE uplisting requirements and readiness timelines. - Evaluate SPAC or de-SPAC-adjacent opportunities, as appropriate, without over-engineering the business. - Interface with investment banks, auditors, securities counsel, and regulatory advisors. - Oversee grant accounting and compliance (e.g., NIH, SBIR/STTR).